This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis (IQUALYSEP)

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2012 by Rennes University Hospital
Information provided by (Responsible Party):
Rennes University Hospital Identifier:
First received: February 8, 2010
Last updated: November 30, 2012
Last verified: November 2012
Cost-effectiveness study of 2 disease-modifying therapies (natalizumab versus mitoxantrone followed by immunomodulator) in the management of aggressive remitting multiple sclerosis

Condition Intervention
Multiple Sclerosis Other: mitoxantrone - immunomodulator Other: natalizumab

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Rennes University Hospital:

Primary Outcome Measures:
  • cost effectiveness [ Time Frame: 30 years ]

Secondary Outcome Measures:
  • progressive neurological disability [ Time Frame: 3 years ]

Estimated Enrollment: 250
Study Start Date: February 2010
Estimated Study Completion Date: February 2019
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: mitoxantrone followed by immunomodulator Other: mitoxantrone - immunomodulator
mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
Active Comparator: natalizumab Other: natalizumab
monthly natalizumab during 3 years


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with remitting multiple sclerosis according to mac Donald criteria
  • aggressive remitting multiple sclerosis according to following criteria:
  • 2 or less disabling relapse during the 12 months before inclusion
  • 1 or more
  • EDSS between 2 and 5
  • aged less or equal to 40 years old for the women
  • effective contraception

Exclusion Criteria:

  • patients less than 18 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01065727

Contact: Le Page Emmanuelle, MD 33-2-9928-5296

CHU Cavale Blanche Recruiting
Brest, France, 29609
Contact: Rouhart Francois, MD   
CHU Rennes Recruiting
Rennes, France, 35033
Contact: Emmauelle Le Page, MD   
Sponsors and Collaborators
Rennes University Hospital
Principal Investigator: Edan Gilles, MD PhD Rennes University Hospital
  More Information

Responsible Party: Rennes University Hospital Identifier: NCT01065727     History of Changes
Other Study ID Numbers: PHRC/09-06
Study First Received: February 8, 2010
Last Updated: November 30, 2012

Keywords provided by Rennes University Hospital:
Reemitting aggressive multiple sclerosis

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Behavioral Symptoms
Immunologic Factors
Adjuvants, Immunologic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017